Canada Spends Logo

Explorez notre analyse du budget 2026

Grant: Master's Award: Canada Graduate Scholarships

McGill University

$17,500.00

Investigating the Interactions of SARS-CoV-2 NSP2/GIGYF2-4EHP Complex and Downstream Effects on Type I Interferon Translation

EF 2023-24

Résumé
COVID-19, caused by the SARS-CoV-2 virus, has been devastating for many across the world. Through examining proteins produced by the SARS-CoV-2 virus, much research has been done to characterize the mechanisms through which the virus develops, progresses, and persists. One such protein is a non-structural protein, termed NSP2, which uses the host’s machinery to evade the immune response. Several host proteins control the expression levels of immune system modulators, or cytokines, by binding to their mRNAs, which are molecular instructions that direct protein production, preventing them from binding to the natural machinery. Previous studies show that NSP2 indirectly represses the production of such immune factors, specifically interferon beta (IFN-?), via the host proteins GIGYF2 and 4EHP. Through interacting with these host proteins, NSP2 bolsters their repressive activity, decreasing levels of IFN-?, and promoting infection. However, the exact process through which NSP2 strengthens repression, as well as the direct interface between NSP2 and these host proteins, has not been discerned. Nonetheless, this mechanism highlights NSP2 as a potential drug target as it contributes to the observed deficiency in generating an immune response. NSP2 can also be used to improve cancer therapies, including oncolytic viruses, which are a form of immunotherapy that specifically targets tumor cells. Through its repression of immune signaling molecules, NSP2 may create an immunosuppressed environment, allowing the virus to enact its anti-tumor activity. This system would have vast applications in the treatment of various cancer types, including lung, breast, and prostate cancer, as well as other viral therapeutics.
Programme
Master's Award: Canada Graduate Scholarships
Bénéficiaire
Emplacement
Quebec, Canada
Type de bénéficiaire
Academia
Type
Grant
Source
CIHR Funding Decisions Database

Tel que publié

Id
505832
Name
Ali Farah
Region
Québec
Country
Canada
Orgtype
Institution Paid; Research Institution
Prcname2
Special Cases - Awards Programs
Projecttitle
Investigating the Interactions of SARS-CoV-2 NSP2/GIGYF2-4EHP Complex and Downstream Effects on Type I Interferon Translation
Programtype2
Studentship Programs
Orgnameinp2
McGill University
Cihramount2
$17,500
Cihrequipment2
$0
Programname2
Master's Award: Canada Graduate Scholarships
Keyworddelim
Antiviral Immunity; Gigyf2/4ehp-Mediated Repression; Mrna 5' Cap Binding; Mrna Translational Control; Oncolytic Virus; Regulation Of Ifn-ß Production; Sars-Cov-2 Immune Evasion; Sars-Cov-2 Nonstructural Protein 2 (Nsp2); Type I Interferons; Vesicular Stomatitis Virus (Vsv)
Abstract
COVID-19, caused by the SARS-CoV-2 virus, has been devastating for many across the world. Through examining proteins produced by the SARS-CoV-2 virus, much research has been done to characterize the mechanisms through which the virus develops, progresses, and persists. One such protein is a non-structural protein, termed NSP2, which uses the host’s machinery to evade the immune response. Several host proteins control the expression levels of immune system modulators, or cytokines, by binding to their mRNAs, which are molecular instructions that direct protein production, preventing them from binding to the natural machinery. Previous studies show that NSP2 indirectly represses the production of such immune factors, specifically interferon beta (IFN-?), via the host proteins GIGYF2 and 4EHP. Through interacting with these host proteins, NSP2 bolsters their repressive activity, decreasing levels of IFN-?, and promoting infection. However, the exact process through which NSP2 strengthens repression, as well as the direct interface between NSP2 and these host proteins, has not been discerned. Nonetheless, this mechanism highlights NSP2 as a potential drug target as it contributes to the observed deficiency in generating an immune response. NSP2 can also be used to improve cancer therapies, including oncolytic viruses, which are a form of immunotherapy that specifically targets tumor cells. Through its repression of immune signaling molecules, NSP2 may create an immunosuppressed environment, allowing the virus to enact its anti-tumor activity. This system would have vast applications in the treatment of various cancer types, including lung, breast, and prostate cancer, as well as other viral therapeutics.
Competitiondate
202312
Approvedterm2
1 yr 0 mth
Pinamesdelim
Ali, Farah
Approvedterm
1 an 0 mois
Cihrcontribution2
~ $17,500~ $0~